RV41.F · Fennec Pharmaceuticals Inc
-
-
1 Comment
Fennec Pharmaceuticals Inc is currently in a long term downtrend where the price is trading 8.6% below its 200 day moving average.
From a valuation standpoint, the stock is 35.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 842.1.
Fennec Pharmaceuticals Inc's total revenue rose by inf% to $170K since the same quarter in the previous year.
Its net income has increased by 10.3% to $-3M since the same quarter in the previous year.
Finally, its free cash flow fell by 106.5% to $-3M since the same quarter in the previous year.
Based on the above factors, Fennec Pharmaceuticals Inc gets an overall score of 3/5.
| ISIN | CA31447P1009 |
|---|---|
| Industry | Biotechnology |
| Sector | Healthcare |
| CurrencyCode | EUR |
| Exchange | F |
| Target Price | 13.6 |
|---|---|
| Market Cap | 204M |
| Dividend Yield | 0.0% |
| PE Ratio | None |
| Beta | 0.11 |
Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. The company's product candidates include PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity hearing loss in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
Learn More